Dr. Anne Sanders was kind enough to write the following synopsis of a recent study on sleep and TMD.
A recent study of the OPPERA group reported in The Journal of Pain, sheds new light on the understanding of poor sleep in relation
After President Obama submits his budget to Congress, the work of Representatives and Senators begins. It is at this time that we tell our elected officials what YOU, TMJ patients, need to have addressed.
The past two months have been busy ones outsid
The Office of the Assistant Secretary for Health at the U.S. Department of Health and Human Services recently released the National Pain Strategy, outlining the federal government's first coordinated plan for reducing the burden of chronic pain that affects millions of Americans. Developed by a diverse team of experts from around the nation, the National Pain Strategy is a road map toward achieving a system of care in which all people receive appropriate, high quality and evidence-based care for pain.
The U.S. Food and Drug Administration (FDA) has issued a consumer warning regarding several safety issues with the entire class of opioid pain medicines. The new safety risks include potentially harmful interactions with numerous other medications, problems with the adrenal glands, and decreased sex hormone levels. The FDA is requiring companies to make changes to the opioid medication labels warning consumers of these risks as described below.